Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  Ä $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

T-Cell Lymphomas - Pipeline Review, H2 2013

Enquire | Email | Print

ISBN: GMDHC4196IDB
Published Date: Oct, 2013
Format: PDF
No of Pages: 124
 
 
Select pricing :
Change Currency: Ä EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Summary

'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indicationís therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directís proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directís team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
- A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Kyowa Hakko Kirin Co., Ltd.
Seattle Genetics, Inc.
Emergent BioSolutions Inc.
Infinity Pharmaceuticals, Inc.
Nippon Kayaku Co., Ltd.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Mundipharma International Limited
Pharmacyclics, Inc.
Chipscreen Biosciences Ltd
Acetylon Pharmaceuticals, Inc.
PharmaMar, S.A.




Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Lymphomas Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for T-Cell Lymphomas 9
T-Cell Lymphomas Therapeutics under Development by Companies 11
T-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
T-Cell Lymphomas Therapeutics - Products under Development by Companies 18
T-Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in T-Cell Lymphomas Therapeutics Development 20
Bristol-Myers Squibb Company 20
Kyowa Hakko Kirin Co., Ltd. 21
Seattle Genetics, Inc. 22
Emergent BioSolutions Inc. 23
Infinity Pharmaceuticals, Inc. 24
Nippon Kayaku Co., Ltd. 25
Celgene Corporation 26
Onyx Pharmaceuticals, Inc. 27
Mundipharma International Limited 28
Pharmacyclics, Inc. 29
Chipscreen Biosciences Ltd 30
Acetylon Pharmaceuticals, Inc. 31
PharmaMar, S.A. 32
T-Cell Lymphomas - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 39
brentuximab vedotin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HBI-8000 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
carfilzomib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
mogamulizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
mogamulizumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PCI-34051 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
forodesine hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
plitidepsin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
lenalidomide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
duvelisib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ricolinostat - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BMS-906024 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NK-314 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug For T-Cell Lymphoma - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Immunotoxins - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
T-Cell Lymphomas Therapeutics - Drug Profile Updates 68
T-Cell Lymphomas Therapeutics - Discontinued Products 107
T-Cell Lymphomas Therapeutics - Dormant Products 108
T-Cell Lymphomas - Product Development Milestones 109
Featured News & Press Releases 109
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 109
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 109
Jun 20, 2013: Acetylon Pharma Announces Presentation Of Preclinical Data Of ACY-1215 For Treatment Of Lymphoma At 12th ICML 112
Jun 12, 2013: Rhizen Pharma Announces Scientific Presentation On Dual PI3K Delta/gamma Inhibitor RP6530 In T-cell Lymphomas At 18th Congress Of EHA 113
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013 113
Jun 02, 2013: Infinity Pharma Reports Presentation Of Updated Phase I Data Of IPI-145 In Chronic Lymphocytic Leukemia At ASCO Annual Meeting 114
May 15, 2013: Topotarget Announces Presentation Of Final data From BELIEF Study With Belinostat At ASCO 2013 117
May 15, 2013: Infinity Pharma Announces Presentation Of Clinical Data On IPI-145 At ASCO 2013 And 12th International Conference On Malignant Lymphoma 118
Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma 119
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 121
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 124
Disclaimer 124

List of Tables
Number of Products Under Development for T-Cell Lymphomas, H2 2013 9
Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Bristol-Myers Squibb Company, H2 2013 20
Kyowa Hakko Kirin Co., Ltd., H2 2013 21
Seattle Genetics, Inc., H2 2013 22
Emergent BioSolutions Inc., H2 2013 23
Infinity Pharmaceuticals, Inc., H2 2013 24
Nippon Kayaku Co., Ltd., H2 2013 25
Celgene Corporation, H2 2013 26
Onyx Pharmaceuticals, Inc., H2 2013 27
Mundipharma International Limited, H2 2013 28
Pharmacyclics, Inc., H2 2013 29
Chipscreen Biosciences Ltd, H2 2013 30
Acetylon Pharmaceuticals, Inc., H2 2013 31
PharmaMar, S.A., H2 2013 32
Assessment by Monotherapy Products, H2 2013 33
Assessment by Stage and Route of Administration, H2 2013 35
Assessment by Stage and Molecule Type, H2 2013 38
T-Cell Lymphomas Therapeutics - Drug Profile Updates 68
T-Cell Lymphomas Therapeutics - Discontinued Products 107
T-Cell Lymphomas Therapeutics - Dormant Products 108

List of Figures
Number of Products under Development for T-Cell Lymphomas, H2 2013 9
Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 33
Assessment by Route of Administration, H2 2013 34
Assessment by Stage and Route of Administration, H2 2013 35
Assessment by Molecule Type, H2 2013 36
Assessment by Stage and Molecule Type, H2 2013 37




 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 346904, price: INR 121047, Global Markets Direct

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online